The ChemQuest Group Appoints New Director
CINCINNATI – The ChemQuest Group Inc. has added Frank Gori as Director, Commercial & Operational Efficiencies in Pharmaceutical, Agricultural and Specialty Chemicals. In this role, Gori will assist clients through ChemQuest’s methodology and tools in uncovering hidden “value levers” in sales, margin, throughput and cost.
With over 30 years of experience in active pharmaceutical ingredient (API) industries, Gori is a recognized subject matter expert in producing APIs and has manufactured hundreds of generic APIs and branded APIs and their intermediates. He has produced 10 new molecular entities and their intermediates for clinical trials, scale-up and commercial launch. In his manufacturing career, Gori managed facilities that produced pharmaceutical APIs, specialty chemicals, biocides, agricultural chemicals and fermented products, and oversaw the manufacturing of the first bio-similar enoxaparin sodium approved by the FDA. He has earned the reputation as a key strategic partner to private equity and investment banking interests specializing in mergers and acquisitions, growth and support strategies, and divestiture activities. Known for his well-rounded business acumen, Gori is a skilled facilitator of successful product manufacturing, technology transfer, plant retrofit, site selection, construction, and (CAPEX) capital investment efforts, as well as mergers and acquisitions.
When asked about his recent hiring decision, Dan Murad, President and CEO of ChemQuest, commented, “We feel confident that Frank’s wealth of domestic and international experience spanning diverse industries, building long-lasting customer relationships through effective manufacturing strategies that are executed to deliver end products on schedule and in full, will be a valuable asset to the ChemQuest business model. Frank Gori’s breadth of technical knowledge (and unrivaled track record) in the highly competitive area of regulatory compliance includes managing FDA and other regulatory audits with no adverse findings, no warning letters and no critical highlights. Full implementation and commercial scale-up follow in a timely and cost-effective manner, which I believe will be immeasurably valuable to ChemQuest’s clients.”